Andy Hsieh
Stock Analyst at William Blair
(0.73)
# 3,773
Out of 4,761 analysts
7
Total ratings
50%
Success rate
-14.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $0.53 | - | 1 | Feb 6, 2025 | |
| ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.61 | - | 1 | Jan 3, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $1.28 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $78.23 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $0.71 | - | 2 | Jun 26, 2023 | |
| ATNM Actinium Pharmaceuticals | Downgrades: Market Perform | n/a | $1.17 | - | 1 | Feb 21, 2023 |
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.53
Upside: -
Elevation Oncology
Jan 3, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.61
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $78.23
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.71
Upside: -
Actinium Pharmaceuticals
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -